STOCKS TELEGRAPH

Tag: RNA Stock Price

  • Avidity (RNA) Sees Stock Surge Following Promising Clinical Trial Results

    Avidity (RNA) Sees Stock Surge Following Promising Clinical Trial Results

    Avidity Biosciences, Inc. (NASDAQ: RNA) is witnessing a significant stock price rise during the current market session. As of the most recent update, RNA stock has climbed 21.75% to $35.20, driven by encouraging data from its clinical trials.

    Positive Data From Phase 1/2 FORTITUDE Trial

    Avidity Biosciences (RNA) announced favorable initial data for AOC 1020 from the Phase 1/2 FORTITUDE trial. The data revealed unprecedented and consistent reductions exceeding 50% in DUX4-regulated genes, alongside trends of functional improvement and favorable safety and tolerability in patients with facioscapulohumeral muscular dystrophy (FSHD).

    The company plans to expedite the initiation of registrational cohorts within the FORTITUDE study. Furthermore, Avidity announced “delpacibart braxlosiran,” which may be shortened to “del-brax,” as the authorized worldwide nonproprietary name for AOC 1020.

    Impact On FSHD Treatment Landscape

    Del-brax stands out as the first investigational therapy specifically designed to address the underlying cause of FSHD, a rare hereditary disorder characterized by relentless muscle function loss, significant pain, fatigue, and progressive disability. Currently, there are no approved therapies for FSHD.

    The early data indicating consistent reductions in DUX4-regulated genes and functional improvements are highly promising, suggesting that del-brax could potentially alter the disease trajectory for FSHD patients.

    Presentation At FSHD Society International Research Congress

    The initial data for AOC 1020 will be presented at the 31st Annual FSHD Society International Research Congress, scheduled for June 13-14, 2024, in Denver, Colorado. Avidity Biosciences, recognizing the urgent need for effective treatments for FSHD, is focusing on accelerating its registrational plans. By targeting the root cause of FSHD, del-brax holds the promise of being a first-in-class, best-in-class therapy.

    This development marks Avidity Biosciences’ third rare muscle disease program to demonstrate delivery to muscle and target engagement, and its second therapy showing signs of functional improvement in patients with rare neuromuscular diseases. These advancements underscore the potential of Avidity’s AOC platform to revolutionize RNA therapeutics and significantly improve patients’ lives.

  • Avidity (RNA) Is Rising After Collaboration Expansion Move

    Avidity (RNA) Is Rising After Collaboration Expansion Move

    In today’s assessment of the US stock charts, Avidity Biosciences, Inc. (NASDAQ: RNA) exhibited a notable surge of 11.04%, reaching $6.84 in the current session. This uptick in Avidity’s stock value is attributable to an expansion move in collaboration.

    Avidity (RNA) has formally disclosed a comprehensive licensing and research collaboration with Bristol Myers Squibb, signaling a collective effort toward the exploration, advancement, and commercialization of various cardiovascular targets. The collaboration is expected to generate a cumulative inflow of $2.3 billion.

    In this collaboration, antibody oligonucleotide conjugates (AOCs) are of critical importance. They combine the targeted efficacy of monoclonal antibodies with the precision of oligonucleotide therapies to address the root causes of previously incurable diseases via RNA therapeutics.

    This strategic collaboration signifies an extension of AOCs’ influence through the amplification of the existing partnership with Bristol Myers Squibb. Concurrently, Avidity maintains its commitment to advancing internal research and development initiatives, particularly in rare cardiac indications.

    According to the agreement’s stipulations, RNA stands to receive an upfront payment of $100 million, inclusive of a $60 million cash component. Furthermore, the agreement encompasses the acquisition of approximately $40 million worth of Avidity common stock at a rate of $7.88 per share.

    RNA is also entitled to potential research and development milestone payments, amounting to around $1.35 billion, with an additional provision for commercial milestone payments totaling up to approximately $825 million. Additionally, tiered royalties, extending to low double-digits on net sales, constitute part of the financial arrangement.

    Bristol Myers Squibb is committed to funding all forthcoming clinical development, regulatory processes, and commercialization endeavors arising from this collaborative initiative. As global leaders in cardiovascular drug discovery and development, Bristol Myers Squibb’s involvement in this strategic collaboration reinforces Avidity’s dedication to advancements in cardiology.

    RNA remains steadfast in progressing its independent research and development initiatives concerning cardiac indications. Avidity aims to extend the applicability of the AOC platform to address debilitating conditions that were hitherto beyond the reach of existing RNA therapies.

    The collaboration with Bristol Myers Squibb stands distinct from Avidity’s internal discovery pipeline, which encompasses research and development candidates targeting rare skeletal muscle conditions and rare cardiac muscle diseases. Avidity is presently advancing three distinct Phase 1/2 programs in the clinic, focusing on rare diseases.